SCHEDULE 13G: Durable Capital Partners LP Discloses 9.9% Stake in Outset Medical, Inc.

Durable Capital Partners LP has filed a Schedule 13G, revealing a significant 9.9% beneficial ownership stake in medical technology company Outset Medical, Inc.

Summary

• Durable Capital Partners LP reported beneficial ownership of 26,609,101 shares of Common Stock in Outset Medical, Inc.
• This stake represents 9.9% of Outset Medical, Inc.'s outstanding Common Stock.
• The ownership percentage is calculated based on 268,778,808 outstanding shares of voting Common Stock, including the full conversion of Series A Non-Voting Convertible Preferred Stock.
• Durable Capital Partners LP, as the investment adviser to Durable Capital Master Fund LP, holds sole voting and dispositive power over these shares.
• The filing indicates that Durable Capital Master Fund LP holds additional Preferred Stock that is not currently convertible due to a Certificate of Designation, which limits beneficial ownership to 9.9% of the Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a Schedule 13G is a factual disclosure, the revelation of a significant stake by a prominent investment firm like Durable Capital Partners LP can be interpreted as a vote of confidence in the company's value or future prospects, which is generally viewed favorably by the market.

Positives

• A significant stake (9.9%) by a reputable institutional investor like Durable Capital Partners LP may signal confidence in Outset Medical, Inc.'s long-term prospects.
• The investment firm has sole voting and dispositive power over a substantial block of shares, indicating a committed position.

Future Outlook

This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing indicates a significant institutional investment in Outset Medical, Inc., a company operating in the medical technology sector, specifically known for its Tablo Hemodialysis System. Such investments can reflect investor sentiment towards the growth potential of innovative medical device companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may influence investor perception and potentially stock price, signaling institutional confidence.
• Company Management: Awareness of a large, active institutional shareholder may influence strategic decisions and corporate governance considerations.

Key Dates

Keywords

Outset Medical, Durable Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Institutional Investor, Medical Technology, SEC Filing